Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology ...

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Shares of Poseida Therapeutics, Inc. PSTX rose sharply in today's pre-market trading after the company agreed to be acquired ...

Investing.com -- Alector Inc.宣布，其用于早期阿尔茨海默症治疗的AL002药物的二期临床试验未能达到减缓疾病进展的主要目标。受此消息影响，该公司股价在盘后交易中暴跌32%。 这家生物制药公司表示，由于试验未能达到主要终点，将终止AL002的长期延伸研究。针对这一发展，Alector还透露计划裁减约17%的员工。

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

Alec­tor re­port­ed a Phase 2 fail­ure for an Ab­b­Vie-part­nered Alzheimer’s pro­gram Mon­day af­ter­noon and said it will ...

It's impossible to miss, but at the same time it's 'hard to see'. However it's unquestionably the 'biggest issue' for this Australian capital, critics say. One Australian hunter said in his 50 ...